Relapse following withdrawal of D-penicillamine from combination (D-penicillamine + zinc) therapy in hepatic Wilson disease.
Kalpana PandaBikrant Bihari LalVikrant SoodRajeev KhannaSeema AlamPublished in: Journal of pediatric gastroenterology and nutrition (2024)
Incidence of relapse after withdrawal of D-pen from combination therapy is 31.8% in hepatic WD. ALT ≥40 U/L, at the time of D-pen stoppage, predicts future relapse.